REQUEST FOR RECORDS DISPOSITION AUTHORITY				JOB NUMBER			
(See Instructions on reverse)				N-088-09-9			
TO: NATIONAL ARCHIVES and RECORDS ADMINISTRATION (NIR) WASHINGTON, DC 20408				DATE RECEIVED 8/17/09			
FROM (Agency or establishment) Department of Health and Human Services				NOTIFICATION TO AGENCY			
2. MAJOR SUBDIVISION				U.S.C. 3	ance with the pr 303a the dispo	sition request.	
Food and Drug Administration (FDA)				including amendments, is approved except for items that may be marked "disposition not			
MINOR SUBDIVISION Center for Biologics Evaluation and Research (CBER)				approved"	or "withdrawn" in	column 10.	
4. NAME OF PERSON WITH WHOM TO CONFER 5. TELEPHONE				DATE ARCHIVIST OF THE UNITED STATES			
Jules Meisler		(301) 827-2863		11-12-09	Edrienne)	C. Shimas	
6. AGENCY CERTIFICATION I hereby certify that I am authorized to act for this agency in matters pertaining to the disposition of its records and that the records proposed for disposal on the attached 55 page(s) are not now needed for the business of this agency or will not be needed after the retention periods specified; and that written concurrence from the General Accounting Office, under the provisions of Title 8 of the GAO Manual for Guidance of Federal Agencies, I is not required;							
8/12/09 Monne X. Wilson HHS R			HS Red	ecords Officer			
7. ITEM NO.	8. DESCRIPTION OF ITEM AND PROPO	OSED DISPOSITION		SUI	GRS OR PERSEDED CITATION	10. ACTION TAKEN (NARA USE ONLY)	
	Unless specifically stated otherwise in the deall items are media-neutral and apply to pape or other media in which records may exist. SEE attached sheet: CBER Information Systems Seung Ja Sinatra - FDA Records Officer Ann Wion - FDA Office of the Chief Counsel	er, electronic, microfor	m,				

LEAVE BLANK (NARA use only)

Information System Records for CBER Programs

File Code: Prefix = CBER

Item Records Description and Authorized Disposition No.

NARA Approved Citation

1 Regulatory Management System - Biologics License Applications (RMS-BLA) Database.

New Related authority item B-31.

Authority Supports managed review process for the review and approval of Biologic License Applications (BLA) for biological derived drugs, blood products and In Vitro Diagnostic (IVD) Test Kits. Interfaces with other CBER information systems including Document Accountability Tracking System (DATS), Biologics Investigational Related Applications Management System (BIRAMS), Blood Establishment Registration (BER) database, Lot Release System (LRS) and Electronic Document Room.

Certain records contain trade secret and confidential commercial information that may not be publicly released; disclosure is subject to the Freedom of Information Act, the Trade Secrets Act, the Privacy Act, and restrictions in other statutes and FDA's implementing regulations.

1.1 RMS-BLA Database -- Data Files.

Provides a summary record of licensed biologic products. Data may be used to prepare ad-hoc reports and to respond to questions concerning the regulation of biologic products, as well as the approval, withdrawal and revocation of BLAs.

Includes submission tracking number (STN), product name, company name, application status (approved, withdrawn, revoked, Refused to File, etc.) and application status date.

Disposition: TEMPORARY

Cut off at the end of the calendar year after final action. Delete/destroy 10 years after cutoff, or when no longer needed for business or reference use, whichever is later.

1.2 RMS-BLA Database Outputs.

Includes reports/queries listing content or portions of the content from RMS-BLA database. These reports/queries are used throughout the review and post-marketing process and provide general application information for information requests.

GRS 20 Items 12 and 16

Disposition: TEMPORARY

Delete/destroy when no longer needed for administrative or reference purposes, whichever is later.

1.3 RMS-BLA Database -- System Documentation.

Includes system operation and user manuals, as well as other system related materials.

GRS 20 Item 11a2

Disposition: PERMANENT

Transfer to the National Archives with the permanent electronic records to which the documentation relates.

2 Lot Release System (LRS) Database.

Supports FDA's lot release program for biologic products. Provides information on sample lots for product approval and on the routine release of lots to market.

New Related Authority Item B-9

Certain records contain trade secret and confidential commercial information that may not be publicly released; disclosure is subject to the Freedom of Information Act, the Trade Secrets Act, the Privacy Act, and restrictions in other statutes and FDA's implementing regulations.

2.1 LRS Database -- Data Files.

System data provides a record of tests performed on product lots that were released or rejected. Data may be used to prepare ad-hoc reports and to respond to questions concerning the regulation, approval, withdrawal and rejection of product lots.

Includes submission tracking number (STN), license number, product name, establishment name, type code, lot number, date sample received, date protocol received, final designation code, and final designation date.

Disposition: TEMPORARY

Cut off at the end of the calendar year after final action. Delete/destroy 20 years after cutoff, or when no longer needed for business or reference use, whichever is later.

2.2 LRS Database - Outputs.

Includes reports/queries listing content or portions of the content from LRS database. These reports/queries are used throughout the lot release process and provide general information for information requests.

GRS 20 Items 12 and 16

Disposition: TEMPORARY

Delete/destroy when no longer needed for administrative or reference purposes, whichever is later.

2.3 LRS Database - System Documentation.

Includes system operation and user manuals, as well as other system related materials.

GRS 20 Item 11a1

Disposition: TEMPORARY

Delete/destroy when superseded or obsolete, or upon authorized deletion of the system, whichever is later.

3 Lot Distribution Database (LDD).

Includes distribution data supplied by the manufacturer on all non-whole blood or tissue biologic products released through distribution channels.

Data is used to quantify the proportion of adverse events received for individual CBER-regulated products, to detect "problem lots," and to track the national supply of products during recalls.

Certain records contain trade secret and confidential commercial information that may not be publicly released; disclosure is subject to the Freedom of Information Act, the Trade Secrets Act, the Privacy Act, and restrictions in other statutes and FDA's implementing regulations.

3.1 LDD -- Data Files

Provides a summary record of product lots reviewed. Data may be used to prepare ad-hoc reports and to respond to questions concerning the regulation, approval, withdrawal and revocation of biologic products.

Includes Document Accountability Tracking System (DATS) log number, product name, submission tracking number (STN), manufacturer name, date of distribution, quantity distributed, quantity returned, expiration date, bulk identification, fill identification, and label lot identification.

Disposition: TEMPORARY

Cutoff at the end of the calendar year the related license is revoked or withdrawn. Delete/destroy 10 years after cutoff, or when no longer needed for business or reference use, whichever is later.

3.2 <u>LDD -- Outputs.</u>

Includes reports/queries listing content or portions of the content from LDD database. These reports/queries are used throughout the lot distribution tracking process and provide general information for information requests.

Disposition: TEMPORARY

Delete/destroy when no longer needed for administrative or reference purposes, whichever is later.

3.3 LDD -- System Documentation.

Includes system operation and user manuals, as well as other system related materials.

New Related Authority Items B-30 & B-31

GRS 20 Items 12 and 16

GRS 20. Item 11a1

Disposition: TEMPORARY

Delete/destroy when superseded or obsolete, or upon authorized deletion of the system, whichever is later.

4 <u>Biologics Investigational Related Applications Management System</u> (BIRAMS).

Used to manage the receipt and review processes for CBER's Investigational Related Applications (IRA) including Investigational New Drug Applications (IND), Investigational Device Exemptions (IDE) and Master Files (MF).

Certain records contain trade secret and confidential commercial information that may not be publicly released; disclosure is subject to the Freedom of Information Act, the Trade Secrets Act, the Privacy Act, and restrictions in other statutes and FDA's implementing regulations.

4.1 **BIRAMS** -- Data Files.

Data may be used to prepare ad-hoc reports and to respond to questions concerning the review of biologic products and master files.

Includes IRA number, sponsor name, IRA title, date submission received, and final action date.

Disposition: TEMPORARY

Cut off at the end of the calendar year after final action. Delete/destroy 30 years after cutoff, or when no longer needed for business or reference use, whichever is later.

4.2 BIRAMS -- Outputs.

Includes reports/queries listing content or portions of the content from BIRAMS database. These reports/queries are used throughout the review and management of the investigational related application and provide general application information for information requests.

Disposition: TEMPORARY

Delete/destroy when no longer needed for administrative or reference purposes, whichever is later.

4.3 BIRAMS -- System Documentation.

Includes system operation and user manuals, as well as other system related materials.

Disposition: TEMPORARY

Delete/destroy when superseded or obsolete, or upon authorized deletion of the system, whichever is later.

Related Authority Items B-10 & B-20

GRS 20 Items 12 and 16

GRS 20 Item 11a1

5 <u>Blood Logging and Tracking (BLT) Database.</u>

Used to maintain data related to the status and review of applications for devices and products related to blood screening and transfusion, as well as other analogous products. Includes application information for 510(k)s, Pre-Market Applications (PMA), modular PMA supplements (PMS), New Drug Applications (NDA), and Abbreviated New Drug Applications (ANDA), as well as related submission correspondence.

New Related Authority Items B-21, B-22 & B-23

Certain records contain trade secret and confidential commercial information that may not be publicly released; disclosure is subject to the Freedom of Information Act, the Trade Secrets Act, the Privacy Act, and restrictions in other statutes and FDA's implementing regulations.

5.1 BLT Database - Data Files.

Provides a summary record of biologic device and drug files. Data may be used to prepare ad-hoc reports and to respond to questions concerning the regulation and review of biologic device and drug products, as well as their status (approved, substantially equivalent, closed, revoked, etc.).

Includes product name, establishment location, final status date, and application status (approved, withdrawal, revoked, substantially equivalent, etc.).

Disposition: TEMPORARY

Cut off at the end of the calendar year after final action. Delete/destroy 30 years after cutoff, or when no longer needed for business or reference use, whichever is later.

5.2 BLT Database — Output Documents.

Includes reports/queries listing content or portions of the content from BLT database. These reports/queries are used throughout the review and post-marketing process and provide general application information for information requests.

GRS 20 Items 12 or 16

Disposition: TEMPORARY

Delete/destroy when no longer needed for administrative or reference purposes, whichever is later.

5.3 BLT Database -- System Documentation.

Includes system operation and user manuals, as well as other system related materials.

GRS 20 Item 11a1

Disposition: TEMPORARY

Delete/destroy when superseded or obsolete, or upon authorized deletion of the system, whichever is later.